BNP Paribas Asset Management
PBYI icon

BNP Paribas Asset Management’s Puma Biotechnology PBYI Stock Holding History

BNP Paribas Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,930
Closed -$692K – 1067
2015
Q1 		$692K Buy
2,930
+953
+48% +$204K 0.01% 895
2014
Q4 		$374K Buy
+1,977
New +$439K ﹤0.01% 884

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BNP Paribas Asset Management's PBYI Position: Q2 2015 in Review

BNP Paribas Asset Management sold out of Puma Biotechnology (PBYI) in Q2 2015, closing a stake of 2,930 shares — an estimated $692K sold.

BNP Paribas Asset Management first reported a position in PBYI in Q4 2014 and held it in 2 quarters. The position peaked at $692K in Q1 2015. 198 funds tracked by Wall St. Rank hold PBYI as of Q2 2015.

  • BNP Paribas Asset Management reported no remaining Puma Biotechnology position as of Q2 2015 after selling out during the quarter.
  • BNP Paribas Asset Management sold 2,930 Puma Biotechnology shares in Q2 2015, an estimated $692K.
  • BNP Paribas Asset Management first reported a position in Puma Biotechnology in Q4 2014 and held it in 2 quarters.
  • BNP Paribas Asset Management's Puma Biotechnology position peaked at $692K in Q1 2015.
  • 198 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2015.

Based on BNP Paribas Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.